Compounds › Verified against primary sources

Thymalin

Russian thymic extract — 293 articles, 13 trials, zero trial registrations

Partially approvedVerified against primary sources

Experimental material. Read before using anything from here.

Nothing on this page is a medical recommendation, prescription or treatment plan. It is an organized translation of protocols circulating in research communities and, where it exists, of what published trials tested. The two are marked differently — and they are not equivalent.

Most of the compounds here have no FDA approval for human use. Several are sold labeled "research use only", which means they have not gone through purity, sterility or dosage controls for human consumption. A community-reported dose is not a validated dose: it is what someone reported having done.

Talk to a licensed health professional before considering any of these compounds. If you already use one and feel anything unexpected, seek care — do not wait for the next routine test.

Specific caution for this compound: The most-cited study on longevity is signed by the compound's own developer. That does not invalidate the work, but it changes the weight given to it.

Summary

Bovine thymus polypeptide extract developed in the Soviet Union in the 1970s by Vladimir Khavinson's group. It is not a single peptide: it is a mixture, with no defined sequence and no purity verifiable on a certificate of analysis. It is the most studied compound in the entire school of short bioregulators — and even so it does not have a single trial registered on ClinicalTrials.gov. This page carries the full survey, with the query used and the caveat for each study.

What it is

Thymalin is not a single peptide. It is a polypeptide extract of bovine thymus, obtained by acid extraction — a mixture, not a defined molecule. This matters more than it seems: there is no sequence to cite, no purity to check on a certificate, and two batches may not be the same thing.

It was developed in the Soviet Union in the 1970s by Vladimir Khavinson's group, at what would become the St. Petersburg Institute of Bioregulation and Gerontology. It is the oldest and most studied compound in the entire school of short bioregulators — the same group that gave rise to Epitalon, Pinealon and Cartalax, which are already in this reference.

How much evidence really exists

This is the part no sales site shows. The numbers below were pulled directly from PubMed and ClinicalTrials.gov on September 4, 2026.

Evidence base	Query	Result
PubMed	`Thymalin`	293 papers
PubMed	`Thymalin AND (Clinical Trial[Publication Type] OR Randomized Controlled Trial[Publication Type])`	13 papers
ClinicalTrials.gov	intervention containing Thymalin	0 records

An honest reading of these numbers

293 papers is a lot for a compound in this family. Prostamax has 6. Thymalin is the outlier, not the rule.
Zero registered trials. No Thymalin study has been registered on ClinicalTrials.gov. Prior registration is what prevents a bad outcome from becoming a different outcome later — without it, there is no way to know how many studies went unpublished.
The 13 trials run from 1999 to 2015 and are mostly in Russian or Ukrainian, published in regional journals.
The most-cited study is by the inventor himself. That does not invalidate the work, but it is information the reader needs in order to calibrate the weight given to it.

The studies behind the claims

According to PubMed, these are the concrete clinical studies behind what is said about Thymalin. Read what each one measured, and in how many people.

Study	N	Context	What it reported	Caveat
Khavinson & Morozov, 2003 Neuro Endocrinol Lett 24(3-4):233-40 · PMID 14523363	266	Elderly, followed for 6–8 years	Mortality 2.0–2.1× lower in the Thymalin group; 4.1× lower in the group that used Thymalin + Epithalamin yearly for 6 years	Signed by the compound's developer. It is the source of practically every longevity claim in circulation
Maslennikov et al., 2007 Probl Tuberk Bolezn Legk (9):30-3 · PMID 18038603	154	Progressive pulmonary tuberculosis	Clinical cure of 61.1% on the standard regimen versus 94.7% on the individualized regimen with immune correction	In Russian. The comparison arm mixes two variables: individualization of the regimen and immunocorrection
Kopchak et al., 2004 Klin Khir (9):5-7 · PMID 15560588	18	Acute necrotizing pancreatitis	Disease regression in 12 of 18; all survived	In Ukrainian. Small series, no control group described
Litvinenko et al., 2015 Bull Exp Biol Med 159(1):62-5 · PMID 26033592	N/A	Chronic salpingitis and oophoritis	Clinical and immunological improvement when the dose was synchronized with the lymphocyte succinate dehydrogenase reaction	The outcome depends on a chronobiology test that is not done in common practice
Musienko, 1999 Lik Sprava (1):119-22 · PMID 10424021	15	Idiopathic Parkinson's disease	Improvement in tremor, rigidity and hypokinesia, with changes in EEG mapping	In Russian. Fifteen patients, no control described

Regulatory status

Russia: registered as an immunomodulating medicine, with decades of use.
Brazil: no registration.
United States and European Union: not approved.
It is imported as a foreign medicine or sold as research material, depending on the supplier.

Why there is no dose table on this page

Because I found no primary source to support one. The doses in circulation come from a Russian package insert translated by a reseller or from community reports — and this page exists precisely so as not to reproduce that as if it were data.

If you have the original Russian package insert in hand, that is the valid reference. A professional who reads Russian or has access to the registration at the Russian Ministry of Health is worth more than any table I could put together here by analogy.

References

This page did not come from the secondary source. Every number was collected by me from the sources listed below, on September 4, 2026, and the query used is stated above.

← Back to all compounds